(RYTM) Rhythm Pharmaceuticals - Overview
Stock: Imcivree, Setmelanotide, Obesity, MC4R, Rare
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 51.2% |
| Relative Tail Risk | -7.47% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.13 |
| Alpha | 57.93 |
| Character TTM | |
|---|---|
| Beta | 0.673 |
| Beta Downside | 0.777 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.07% |
| CAGR/Max DD | 1.29 |
Description: RYTM Rhythm Pharmaceuticals January 09, 2026
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a Boston-based commercial-stage biopharma focused on rare neuroendocrine disorders, primarily obesity driven by genetic defects in the melanocortin-4 (MC4R) pathway.
The company’s flagship product, IMCIVREE (setmelanotide), is an MC4R agonist already approved by the FDA for obesity associated with POMC, LEPR, Bardet-Biedl, and Alström syndromes. It is now in Phase 3 trials expanding into heterozygous POMC/LEPR deficiency, SRC-1 deficiency, SH2B1 deficiency, MC4R deficiency, and other MC4R-related conditions.
As of the most recent 10-Q (Q3 2024), Rhythm reported $210 million in cash and marketable securities, sufficient for >12 months of operating runway, and generated $62 million in net product revenue from IMCIVREE, reflecting a 38 % YoY growth driven by new label expansions. The company’s licensing network-including agreements with LG Chem, Ipsen, Camurus, RareStone, and a joint research collaboration with Axovia-provides both upfront payments and milestone potential that could materially augment cash flow.
Key sector dynamics include the U.S. rare-disease drug market’s projected CAGR of ~10 % through 2030 and growing payer willingness to cover high-cost, high-impact therapies for genetically defined obesity, though reimbursement uncertainty and competition from emerging gene-therapy approaches remain material risks. For a deeper dive into Rhythm’s valuation assumptions and how they compare to peers, a quick look at ValueRay’s analyst toolkit can be a useful next step.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -192.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 23.69 > 1.0 |
| NWC/Revenue: 224.0% < 20% (prev 215.7%; Δ 8.31% < -1%) |
| CFO/TA -0.22 > 3% & CFO -109.1m > Net Income -192.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.3m) vs 12m ago 5.11% < -2% |
| Gross Margin: 89.40% > 18% (prev 0.89%; Δ 8852 % > 0.5%) |
| Asset Turnover: 40.06% > 50% (prev 30.95%; Δ 9.11% > 0%) |
| Interest Coverage Ratio: -7.96 > 6 (EBITDA TTM -169.0m / Interest Expense TTM 21.4m) |
Altman Z'' -9.79
| A: 0.77 (Total Current Assets 494.8m - Total Current Liabilities 104.3m) / Total Assets 506.9m |
| B: -2.57 (Retained Earnings -1.30b / Total Assets 506.9m) |
| C: -0.39 (EBIT TTM -170.5m / Avg Total Assets 435.2m) |
| D: -3.65 (Book Value of Equity -1.31b / Total Liabilities 358.1m) |
| Altman-Z'' Score: -9.79 = D |
Beneish M -3.12
| DSRI: 1.10 (Receivables 33.0m/19.3m, Revenue 174.3m/112.5m) |
| GMI: 0.99 (GM 89.40% / 88.61%) |
| AQI: 0.33 (AQ_t 0.02 / AQ_t-1 0.05) |
| SGI: 1.55 (Revenue 174.3m / 112.5m) |
| TATA: -0.16 (NI -192.3m - CFO -109.1m) / TA 506.9m) |
| Beneish M-Score: -3.12 (Cap -4..+1) = AA |
What is the price of RYTM shares?
Over the past week, the price has changed by +1.06%, over one month by +4.21%, over three months by +5.20% and over the past year by +72.65%.
Is RYTM a buy, sell or hold?
- StrongBuy: 8
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RYTM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 141.6 | 36.6% |
| Analysts Target Price | 141.6 | 36.6% |
| ValueRay Target Price | 157.7 | 52.2% |
RYTM Fundamental Data Overview February 03, 2026
P/B = 45.97
Revenue TTM = 174.3m USD
EBIT TTM = -170.5m USD
EBITDA TTM = -169.0m USD
Long Term Debt = 4.14m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 624.0k USD (from shortTermDebt, last quarter)
Debt = 151.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 98.9m USD (from netDebt column, last quarter)
Enterprise Value = 6.58b USD (6.84b + Debt 151.0m - CCE 416.1m)
Interest Coverage Ratio = -7.96 (Ebit TTM -170.5m / Interest Expense TTM 21.4m)
EV/FCF = -60.26x (Enterprise Value 6.58b / FCF TTM -109.1m)
FCF Yield = -1.66% (FCF TTM -109.1m / Enterprise Value 6.58b)
FCF Margin = -62.60% (FCF TTM -109.1m / Revenue TTM 174.3m)
Net Margin = -110.3% (Net Income TTM -192.3m / Revenue TTM 174.3m)
Gross Margin = 89.40% ((Revenue TTM 174.3m - Cost of Revenue TTM 18.5m) / Revenue TTM)
Gross Margin QoQ = 89.28% (prev 88.57%)
Tobins Q-Ratio = 12.98 (Enterprise Value 6.58b / Total Assets 506.9m)
Interest Expense / Debt = 3.14% (Interest Expense 4.74m / Debt 151.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -134.7m (EBIT -170.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.75 (Total Current Assets 494.8m / Total Current Liabilities 104.3m)
Debt / Equity = 1.01 (Debt 151.0m / totalStockholderEquity, last quarter 148.8m)
Debt / EBITDA = -0.59 (negative EBITDA) (Net Debt 98.9m / EBITDA -169.0m)
Debt / FCF = -0.91 (negative FCF - burning cash) (Net Debt 98.9m / FCF TTM -109.1m)
Total Stockholder Equity = 116.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.19% (Net Income -192.3m / Total Assets 506.9m)
RoE = -165.6% (Net Income TTM -192.3m / Total Stockholder Equity 116.1m)
RoCE = -141.7% (out of range, set to none) (EBIT -170.5m / Capital Employed (Equity 116.1m + L.T.Debt 4.14m))
RoIC = -303.3% (out of range, set to none) (NOPAT -134.7m / Invested Capital 44.4m)
WACC = 8.26% (E(6.84b)/V(6.99b) * Re(8.39%) + D(151.0m)/V(6.99b) * Rd(3.14%) * (1-Tc(0.21)))
Discount Rate = 8.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.25%
Fair Price DCF = unknown (Cash Flow -109.1m)
EPS Correlation: 35.16 | EPS CAGR: 16.31% | SUE: 1.65 | # QB: 1
Revenue Correlation: 79.98 | Revenue CAGR: 143.7% | SUE: 0.16 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.77 | Chg30d=+0.013 | Revisions Net=+1 | Analysts=9
EPS next Year (2026-12-31): EPS=-2.64 | Chg30d=-0.023 | Revisions Net=-1 | Growth EPS=+15.1% | Growth Revenue=+56.1%